This content is accessible only to 2020 ASCRS Virtual Annual Meeting attendees. If you attended the virtual meeting, please log in with the account associated with your virtual meeting registration. To log in, click the teal "Login" button in the upper right-hand corner of this page.
To describe a novel minimally invasive surgical technique for treatment of open-angle glaucoma. Initial papers describe gonioscopic-transluminal trabeculotomy as a circumferential procedure. The authors describe a novel procedure with 180-degree trabeculotomy followed by viscoelastic canaloplasty (viscocanaloplasty).
This was a pilot project describing initial results in a small case series (n=8) of patients undergoing hemi-gonioscopic-assisted transluminal trabeculotomy (Hemi GATT) with direct viscocanaloplasty.
This was a pilot project (n=26) of patients undergoing hemi-gonioscopic-assisted transluminal trabeculotomy (Hemi GATT) with direct viscocanaloplasty. The mean age was 69 years (Range 24-87). Preoperatively the mean intraocular pressure (IOP) was 16 mmHg (Range 7-37) and patients were on an average of 2.8 IOP lowering drops. Average daily dose of diamox was 466mg (n=11). IOP lowering was significantly lower at 6 months follow up (p=0.05) with a mean IOP of 13 mmHg. IOP lowering medications were reduced significantly to an average of 1.6. Only one patient remained on diamox (375 mg daily). One patient developed CME and two patients had IOP spikes that were managed medically.
The results suggest that Hemi-GATT with direct viscocanaloplasty provides significant reductions in IOP as well as reduces reliance on oral diamox and topical IOP lowering medications. Ongoing evaluation is required to establish safety and efficacy especially when compared to hemi-GATT alone or circumferential GATT.
This presentation is from the session "SPS-105 Minimally Invasive Glaucoma Surgery: Viscocanalostomy, Combined Procedures, Outcomes" from the 2020 ASCRS Virtual Annual Meeting held on May 16-17, 2020.